Product Description
Ceftazidime injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ceftazidime-injection-route/side-effects/drg-20073334?p=1)
Mechanisms of Action: PBP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Urinary Tract Infections | Nephritis | Pyelonephritis
Known Adverse Events: Constipation
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan, Spain, Thailand
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Fractures, Open|Pneumonia
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Melioidosis|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections
Phase 1: Pneumonia, Ventilator-Associated
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Unknown Status |
Fractures, Open |
2027-12-31 |
|
| ARV-1801-001 | P2 |
Completed |
Melioidosis |
2023-10-10 |
24% |
| ARV-1801-001 | P2 |
Completed |
Melioidosis |
2023-10-10 |
24% |
| jRCT2061210026 | P3 |
Completed |
Unknown |
2022-09-15 |
|
| ASPIC | P3 |
Active, not recruiting |
Pneumonia|Acute Respiratory Distress Syndrome |
2021-07-27 |